Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Register now for the “Q4 Earnings Season Wrap-Up.”
Join stock market expert Marc Chaikin (the creator of Chaikin Money Flow) and Explosive Options’ Bob Lang for a special earnings season wrap-up.

You’ll find out the biggest takeaways from recent earnings results and what it means for the market—and YOUR money. 

Menu

Oragenics Inc (OGEN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 26,487
  • Shares Outstanding, K 29,433
  • Annual Sales, $ 0 K
  • Annual Income, $ -6,730 K
  • 36-Month Beta 1.72
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.39
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.15
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 02/22/19
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.86 +4.65%
on 01/31/19
1.06 -15.09%
on 01/28/19
-0.08 (-8.16%)
since 01/18/19
3-Month
0.70 +28.57%
on 12/20/18
1.67 -46.11%
on 12/03/18
+0.10 (+12.50%)
since 11/20/18
52-Week
0.38 +136.84%
on 09/07/18
4.20 -78.57%
on 03/07/18
-0.97 (-51.87%)
since 02/20/18

Most Recent Stories

More News
Genprex Appoints John N. Bonfiglio, PhD, to Board of Directors

Genprex, Inc. (NASDAQ: GNPX) a clinical-stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, announced...

OGEN : 0.90 (-3.23%)
TPIV : 8.34 (+0.60%)
GNPX : 1.42 (-4.70%)
Safer Treatments Gain Market Traction as Cancer Occurence Continues to Grow

FinancialBuzz.com News Commentary

RNN : 0.58 (+3.57%)
OGEN : 0.90 (-3.23%)
ONCS : 0.60 (-4.80%)
SNETD : 0.3900 (+14.71%)
SNET : 0.0190 (+21.02%)
SNSS : 0.55 (+1.85%)
Oragenics, Inc. Receives Further Validation for Lantibiotic Compound OG716

Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis ("OM"), today announces the publication...

OGEN : 0.90 (-3.23%)
Oragenics Inc. to Present at NobleCon15 on January 28, 2019

Oragenics, Inc. (NYSE American:OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis ("OM"), announced today that Alan...

OGEN : 0.90 (-3.23%)
Stimulated Development of Orphan Drug Designations for Rare Diseases and Anti-Cancer Drug Candidates Intensifies

The FDA is committed to doing what is can to stimulate the development of more products by improving the consistency and efficiency fueling biotech and pharma companies in the pharmaceutical industry forge...

OGEN : 0.90 (-3.23%)
AZN : 40.53 (+0.17%)
CLVS : 24.24 (-0.53%)
NVLN : 1.30 (-0.76%)
MBRX : 1.33 (+1.53%)
Oragenics, Inc. Announces Publication Detailing the Development of Blueprints for Designing a New Class of Anti-Infectives

Oragenics, Inc. (NYSE American: OGEN) (the "Company"), a clinical stage biotechnology company, today announced the publication of a research paper titled "Blueprints for the rational design...

OGEN : 0.90 (-3.23%)
Oragenics, Inc. to Present at the 11th Annual LD Micro Main Event

LOS ANGELES, CA / ACCESSWIRE / November 26, 2018 / Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis...

OGEN : 0.90 (-3.23%)
Recent Analysis Shows Liberty Global, New Oriental Education & Technology Group, Platinum Group Metals, Asure Software, Oragenics, and MGE Energy Market Influences -- Renewed Outlook, Key Drivers of Growth

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Liberty Global PLC (NASDAQ:LBTYA),...

ASUR : 6.56 (+7.72%)
OGEN : 0.90 (-3.23%)
EDU : 79.28 (+3.20%)
LBTYA : 25.64 (+0.39%)
PLG : 1.52 (-0.65%)
LBTYK : 24.78 (+0.20%)
MGEE : 65.68 (-0.20%)
Oragenics, Inc. Announces 3Q 2018 Financial Results and Provides Corporate Update

Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis, announced financial results...

OGEN : 0.90 (-3.23%)
XON : 7.95 (+1.66%)
Intrexon (XON) Reports Narrower-Than-Expected Loss in Q3

Intrexon (XON) incurs narrower-than-expected loss, while revenues miss estimates in the third quarter of 2018.

OGEN : 0.90 (-3.23%)
XON : 7.95 (+1.66%)
ZIOP : 2.72 (+4.62%)
FCSC : 1.94 (-4.43%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More Share

Trade OGEN with:

Business Summary

Oragenics Inc is a biotechnology company focused on the development and licensure of innovative products and technologies for improving human health.

See More

Key Turning Points

2nd Resistance Point 0.95
1st Resistance Point 0.93
Last Price 0.90
1st Support Level 0.89
2nd Support Level 0.87

See More

52-Week High 4.20
Fibonacci 61.8% 2.74
Fibonacci 50% 2.29
Fibonacci 38.2% 1.84
Last Price 0.90
52-Week Low 0.38

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar